PMV Pharma

PMV Pharma's mission is to conquer cancer by restoring the function of the most frequently mutated tumor suppressor, p53. The company's key achievement is advancing rezatapopt, a first-in-class p53 Y220C reactivator, into a pivotal Phase 1/2 trial (PYNNACLE) with Fast Track designation and publishing compelling first-in-human data in the New England Journal of Medicine. Its strategy leverages a deep structural biology platform to develop tumor-agnostic therapies targeting specific p53 hotspot mutations, aiming to address a major unmet need in approximately 50% of all cancers.

A precision oncology platform for designing small molecules that structurally correct specific mutant p53 proteins, restoring their wild-type tumor suppressor function through targeted binding to mutation-induced pockets.

PMV is a leader in small molecule p53 reactivation, with its lead asset rezatapopt being the most advanced mutation-specific candidate. Competition includes other p53-targeting approaches (e.g., Aprea's failed eprenetapopt) and indirect competition from standard oncology therapies. PMV's key advantages are its foundational science, precise structural approach, and first-in-human clinical validation published in the NEJM.